MAPT and Alzheimer disease: Simulations showed that a two-step approach (that is, plasma p-tau217 first, followed by tau-PET in individuals with high plasma p-tau217 only) could substantially reduce the number and the cost of recruiting participants for a preclinical AD clinical trial with change in mPACC5 or progression to MCI as the primary endpoint.